+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Amyotrophic Lateral Sclerosis Treatment Market 2019-2023 - Product Image

Global Amyotrophic Lateral Sclerosis Treatment Market 2019-2023

  • ID: 4747532
  • Report
  • December 2018
  • Region: Global
  • 103 pages
  • TechNavio
UP TO OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • ITALFARMACO
  • Mitsubishi Tanabe Pharma
  • Sanofi
  • MORE
Initiatives to increase R&D for new amyotrophic lateral sclerosis therapies will boost the growth of the market. This increase in R&D for new amyotrophic lateral sclerosis therapies is due to the increase in number of cases of amyotrophic lateral sclerosis. The analysts have predicted that the amyotrophic lateral sclerosis treatment market will register a CAGR of almost 20% by 2023.

Market Overview

Increase in incidence and prevalence of ALS

The incidence and prevalence of amyotrophic lateral sclerosis is increasing. Amyotrophic lateral sclerosis is commonly known as Lou Gehrig's disease. which is a progressive and fatal neuromuscular disease for which a cure is yet to be identified. The hereditary form of amyotrophic lateral sclerosis is known as familial amyotrophic lateral sclerosis. and it occurs in 5% to 10% of the cases.

Patent expiry of drugs

Loss of patents and market exclusivity of drugs create opportunities for the sales of low-cost alternative drugs, which may decrease the sales of approved drugs. Currently. the market has two drugs, which can delay the progression of the disease and are approved for the treatment of amyotrophic lateral sclerosis.

For the detailed list of factors that will drive and challenge the growth of the amyotrophic lateral sclerosis treatment market during the 2019-2023, view this report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Mitsubishi Tanabe Pharma and Sanofi, the competitive environment is quite intense. Factors such as initiatives to increase R&D for new amyotrophic lateral sclerosis therapies and the increase in incidence and prevalence of ALS, will provide considerable growth opportunities to amyotrophic lateral sclerosis treatment manufactures. ITALFARMACO, Mitsubishi Tanabe Pharma, and Sanofi are some of the major companies covered in this report.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • ITALFARMACO
  • Mitsubishi Tanabe Pharma
  • Sanofi
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: PIPELINE ANALYSIS
  • Pipeline analysis
PART 05: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 07: MARKET SEGMENTATION BY TYPE
  • Market segmentation by type
  • Comparison by type
  • Intravenous - Market size and forecast 2018-2023
  • Oral - Market size and forecast 2018-2023
  • Market opportunity by type
PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Market trends
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • ITALFARMACO
  • Mitsubishi Tanabe Pharma
  • Sanofi
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Global central nervous system (CNS) disorders drugs market
Exhibit 02: Segments of global central nervous system (CNS) disorders drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Late-stage pipeline drugs for ALS
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Type - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Intravenous - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Intravenous - Year-over-year growth 2019-2023 (%)
Exhibit 22: Oral - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Oral - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 30: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 32: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 34: Key leading countries
Exhibit 35: Market opportunity
Exhibit 36: Pipeline drugs for ALS
Exhibit 37: Impact of drivers and challenges
Exhibit 38: Vendor landscape
Exhibit 39: Landscape disruption
Exhibit 40: Vendors covered
Exhibit 41: Vendor classification
Exhibit 42: Market positioning of vendors
Exhibit 43: ITALFARMACO - Vendor overview
Exhibit 44: ITALFARMACO - Organizational developments
Exhibit 45: ITALFARMACO - Key offerings
Exhibit 46: Mitsubishi Tanabe Pharma - Vendor overview
Exhibit 47: Mitsubishi Tanabe Pharma - Business segments
Exhibit 48: Mitsubishi Tanabe Pharma - Organizational developments
Exhibit 49: Mitsubishi Tanabe Pharma - Geographic focus
Exhibit 50: Mitsubishi Tanabe Pharma - Key offerings
Exhibit 51: Sanofi - Vendor overview
Exhibit 52: Sanofi - Business segments
Exhibit 53: Sanofi - Organizational developments
Exhibit 54: Sanofi - Geographic focus
Exhibit 55: Sanofi - Segment focus
Exhibit 56: Sanofi - Key offerings
Exhibit 57: Validation techniques employed for market sizing
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • ITALFARMACO
  • Mitsubishi Tanabe Pharma
  • Sanofi
  • MORE
Global Amyotrophic Lateral Sclerosis Treatment Market 2019-2023

The author recognizes the following companies as the key players in the global amyotrophic lateral sclerosis treatment market: ITALFARMACO, Mitsubishi Tanabe Pharma, and Sanofi.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the initiatives to increase R&D for new amyotrophic lateral sclerosis therapies.”

According to the report, one of the major drivers for this market is the increase in incidence and prevalence of ALS.

Further, the report states that one of the major factors hindering the growth of this market is the patent expiry of drugs.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • ITALFARMACO
  • Mitsubishi Tanabe Pharma
  • Sanofi
Note: Product cover images may vary from those shown
Adroll
adroll